AstraZeneca sees stock market value slump by more than £20bn after drug setback

Yorkshire Post — Jul 09, 10:47 AM

AstraZeneca has seen more than £20 billion wiped off its stock market value after being hit by a setback in a trial for a new drug to treat heart disease.

Read full article at Yorkshire Post →

AstraZeneca Shares Plunge on Drug Trial Failure

AstraZeneca stock plunges after late-stage heart drug trial misses its target Quartz — Jul 09, 11:20 AM
AstraZeneca sees stock market value slump by more than £20bn after drug setback The Argus — Jul 09, 10:39 AM